Drug Trial Radar · NCT05251714
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
May 27, 2022
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Treadwell Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
Conditions
- Advanced Solid Tumor
- Breast Cancer
Interventions
CFI-402257Drug
Oral once daily in 28 day cycles
FulvestrantDrug
500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the incidence of adverse events of CFI-402257 as a single agent and at the recommended phase 2 dose (RP2D)Time frame: 48 months
- To assess the incidence of adverse events of CFI-402257 in combination with fulvestrant and at the recommended phase 2 dose (RP2D)Time frame: 48 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
START San Antonio
San Antonio, Texas
START - Mountain Region
West Valley City, Utah
Virginia Cancer Specialist
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.